Arrowstreet Capital’s Health Catalyst HCAT Stock Holding History

Arrowstreet Capital’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,178	Closed	-$294K	–	1336
2023 Q1	$294K	Buy	+25,178	New	+$321K	﹤0.01%	1245

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Daventry Group New York $87.8M AUM 3.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arrowstreet Capital's HCAT Position: Q2 2023 in Review

Arrowstreet Capital sold out of Health Catalyst (HCAT) in Q2 2023, closing a stake of 25,178 shares — an estimated $294K sold.

Arrowstreet Capital first reported a position in HCAT in Q1 2023 and held it in 1 quarter. The position peaked at $294K in Q1 2023. 154 funds tracked by Wall St. Rank hold HCAT as of Q2 2023.

Arrowstreet Capital reported no remaining Health Catalyst position as of Q2 2023 after selling out during the quarter.
Arrowstreet Capital sold 25,178 Health Catalyst shares in Q2 2023, an estimated $294K.
Arrowstreet Capital first reported a position in Health Catalyst in Q1 2023 and held it in 1 quarter.
Arrowstreet Capital's Health Catalyst position peaked at $294K in Q1 2023.
154 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2023.

Based on Arrowstreet Capital's 13F filing for Q2 2023, filed 14 Aug 2023.